Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Spectral on Linkedin Today

<< Previous

Bullboard Posts

Next >>

Post by TechOneon Dec 06, 2024 3:42pm

140 Views

Post# 36350032

Spectral on Linkedin Today

Understanding Endotoxin Detection: EAA™ vs. LAL Assay

The Endotoxin Activity Assay (EAA™) and the Limulus Amebocyte Lysate (LAL) assay are two prominent methods for detecting endotoxins, but their methodologies and applications vary significantly. Here's a breakdown:

Methodology

• EAA™: Measures neutrophil activation, rapidly assessing endotoxin levels in whole blood.
• LAL Assay: Utilizes lysate from horseshoe crab blood, detecting endotoxin through coagulation reactions.

Sensitivity and Specificity

• EAA™: Optimized for low endotoxin concentrations, effective in clinical scenarios, and has been correlated with patient outcomes.
• LAL Assay: a quantitative test for endotoxin measurement in crystalloid solutions, but cannot accurately detect endotoxin in whole blood or plasma.

In summary:

• The EAA™ is ideal for semi-quantitative analysis of endotoxins in whole blood, suitable for clinical use.
• The LAL Assay is best for precise endotoxin detection in crystalloid solutions but not appropriate for blood-based samples.

Understanding these differences can help in choosing the right assay for specific research or clinical applications. Learn more: https://buff.ly/3ZyGoYJ

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project